Get the Stockscreener App
2.00
1.01%
0.02
After Hours:
2.00
Celularity Inc stock is traded at $2.00, with a volume of 13,200.
It is up +1.01% in the last 24 hours and up +0.00% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$1.98
Open:
$1.96
24h Volume:
13,200
Relative Volume:
0.09
Market Cap:
$56.66M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.2761
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
+14.29%
1M Performance:
+0.00%
6M Performance:
-14.89%
1Y Performance:
-0.50%
1-Day Range:
$1.96
$2.00
1-Week Range:
$1.77
$2.29
52-Week Range:
$1.06
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.00 | 56.09M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity Inc. (CELU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Celularity, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
[Form 4] Celularity Inc Insider Trading Activity - Stock Titan
Form 4: Celularity (CELU) director now holds 248,765 Class A shares - Stock Titan
Is Celularity Inc. Equity Warrant stock attractive after correctionWeekly Trading Summary & Expert Verified Movement Alerts - newser.com
Will Celularity Inc. Equity Warrant stock attract more institutional investors - newser.com
Is Celularity Inc a good long term investmentLarge Cap Stability Picks & Accelerated Capital Growth - earlytimes.in
Chart based analysis of Celularity Inc. Equity Warrant trendsQuarterly Profit Report & Safe Capital Preservation Plans - newser.com
Will Celularity Inc. Equity Warrant stock maintain momentum in 20252025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Quantitative breakdown of Celularity Inc. Equity Warrant recent moveQuarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
Using data models to predict Celularity Inc. Equity Warrant stock movementTrade Entry Report & AI Enhanced Trading Alerts - newser.com
Can Celularity Inc. Equity Warrant stock beat market expectations this quarterMarket Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Backtesting results for Celularity Inc. trading strategiesWeekly Profit Report & Long-Term Capital Growth Ideas - newser.com
Should you wait for a breakout in Celularity Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
What analysts say about Celularity Inc stockSector Leadership Analysis & Ride the Wave of Market-Beating Growth - earlytimes.in
What does recent volatility data suggest for Celularity Inc.Forecast Cut & High Accuracy Trade Alerts - newser.com
Is Celularity Inc. Equity Warrant stock attractive for long term wealth buildingWeekly Trend Recap & Capital Efficiency Focused Ideas - newser.com
LEVIEN VINCENT Insider Trades - Nasdaq
How to use a screener to detect Celularity Inc. Equity Warrant breakoutsJuly 2025 PostEarnings & Fast Entry Momentum Trade Alerts - newser.com
What momentum shifts mean for Celularity Inc. Equity WarrantTrade Signal Summary & Technical Pattern Based Signals - newser.com
How to interpret RSI for Celularity Inc. Equity Warrant stockRecession Risk & Trade Opportunity Analysis - newser.com
Is Celularity Inc. Equity Warrant stock entering bullish territoryMarket Volume Summary & Smart Investment Allocation Insights - newser.com
Why Celularity Inc. stock remains a top recommendationJuly 2025 Action & Fast Entry and Exit Trade Plans - newser.com
Detecting support and resistance levels for Celularity Inc. Equity Warrant2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Has Celularity Inc. Equity Warrant formed a bullish divergenceMarket Growth Summary & Community Consensus Picks - newser.com
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):